These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 36573545)
1. High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020-April 2021), Democratic Republic of the Congo. Munyeku-Bazitama Y; Folefack GT; Yambayamba MK; Tshiminyi PM; Kazenza BM; Otshudiema JO; Guinko NT; Umba MD; Mulumba A; Baketana LK; Mukadi PK; Smith C; Muyembe-Tamfum JJ; Ahuka-Mundeke S; Makiala-Mandanda S Emerg Infect Dis; 2023 Jan; 29(1):89-97. PubMed ID: 36573545 [TBL] [Abstract][Full Text] [Related]
2. High Prevalence of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (Anti-SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey. Nkuba AN; Makiala SM; Guichet E; Tshiminyi PM; Bazitama YM; Yambayamba MK; Kazenza BM; Kabeya TM; Matungulu EB; Baketana LK; Mitongo NM; Thaurignac G; Leendertz FH; Vanlerberghe V; Pelloquin R; Etard JF; Maman D; Mbala PK; Ayouba A; Peeters M; Muyembe JT; Delaporte E; Ahuka SM Clin Infect Dis; 2022 Mar; 74(5):882-890. PubMed ID: 34089598 [TBL] [Abstract][Full Text] [Related]
3. Seroprevalence of COVID-19 infection in a densely populated district in the eastern Democratic Republic of Congo. Irenge LM; Bulakali HM; Akonkwa AI; Ambroise J; Gala JL Epidemiol Infect; 2023 Feb; 151():e24. PubMed ID: 36775822 [TBL] [Abstract][Full Text] [Related]
4. High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May-October 2021) in Matadi, Democratic Republic of the Congo. Munyeku-Bazitama Y; Okitale-Talunda P; Mpingabo-Ilunga P; Yambayamba MK; Tshiminyi PM; Umba-Phuati A; Kimfuta J; Phukuta FA; Makindu G; Mufwaya-Nsene R; Asari R; Makimoto S; Baketana LK; Ahuka-Mundeke S; Isono M; Nsio-Mbeta J; Makiala-Mandanda S; Muyembe-Tamfum JJ Open Forum Infect Dis; 2023 Jan; 10(1):ofad023. PubMed ID: 36726537 [TBL] [Abstract][Full Text] [Related]
5. COVID-19 seroprevalence cohort survey among health care workers and their household members in Kinshasa, DR Congo, 2020-2022. Madinga J; Mbala-Kingebeni P; Nkuba-Ndaye A; Baketana-Kinzonzi L; Matungulu-Biyala E; Mutombo-Lupola P; Seghers CA; Smekens T; Ariën KK; Van Damme W; Kalk A; Peeters M; Ahuka-Mundeke S; Muyembe-Tamfum JJ; Vanlerberghe V J Health Popul Nutr; 2024 Jun; 43(1):74. PubMed ID: 38824595 [TBL] [Abstract][Full Text] [Related]
6. [Seroprevalence of SARS-CoV-2 antibodies among travellers and workers screened at the Saint Luc Clinic in Bukavu, a city in eastern Democratic Republic of the Congo, from May to August 2020]. Katchunga PB; Murhula A; Akilimali P; Zaluka JC; Karhikalembu R; Makombo M; Bisimwa J; Mubalama E Pan Afr Med J; 2021; 38():93. PubMed ID: 33889259 [TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of anti-SARS-CoV-2 antibodies and risk of viral exposure among healthcare workers in the South Kivu province, eastern Democratic Republic of the Congo: a cross-sectional study. Chasinga TB; Cikwanine JB; Kribi S; Yoyu JT; Hofmann N; Grossegesse M; Nitsche A; Tomczyk S; Vietor AC; Leendertz FH; Eckmanns T; Kusinza AB; Munguakonkwa E; Kalk A; Raha M; Kambale NS; Ayagirwe RB; Schubert G; Mukwege D BMJ Open; 2024 Jan; 14(1):e072212. PubMed ID: 38176860 [TBL] [Abstract][Full Text] [Related]
8. Prevalence of anti-SARS-CoV-2 antibodies in people attending the two main Goma markets in the eastern Democratic Republic of the Congo. Mitangala PN; Irenge LM; Musubao ET; Kahindo JBM; Ayonga PN; Kyembwa Safari I; Kubuya JB; Ntabe EN; Kabangwa Senga RK; Mutombo GN; Ambroise J; Gala JL Epidemiol Infect; 2023 Sep; 151():e167. PubMed ID: 37724000 [TBL] [Abstract][Full Text] [Related]
13. Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon. Ndongo FA; Guichet E; Mimbé ED; Ndié J; Pelloquin R; Varloteaux M; Esemu L; Mpoudi-Etame M; Lamare N; Edoul G; Wouambo RK; Djomsi DM; Tongo M; Tabala FN; Dongmo RK; Diallo MSK; Bouillin J; Thaurignac G; Ayouba A; Peeters M; Delaporte E; Bissek AZ; Mpoudi-Ngolé E Emerg Infect Dis; 2022 Jun; 28(6):1233-1236. PubMed ID: 35470795 [TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19). Kislaya I; Gonçalves P; Gómez V; Gaio V; Roquette R; Barreto M; Sousa-Uva M; Torres AR; Santos J; Matos R; Manita C; Almeida Santos J; Soeiro S; de Sousa R; Costa I; Verdasca N; Guiomar R; Rodrigues AP; Infect Dis (Lond); 2022 Jun; 54(6):418-424. PubMed ID: 35023439 [TBL] [Abstract][Full Text] [Related]
15. High pre-Delta and early-Omicron SARS-CoV-2 seroprevalence detected in dried blood samples from Kinshasa (D.R. Congo). de Aguirre PM; Carlos S; Pina-Sánchez M; Mbikayi S; Burgueño E; Tendobi C; Chiva L; Holguín Á; Reina G J Med Virol; 2024 Mar; 96(3):e29529. PubMed ID: 38516764 [TBL] [Abstract][Full Text] [Related]
16. High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo. Batchi-Bouyou AL; Lobaloba Ingoba L; Ndounga M; Vouvoungui JC; Mfoutou Mapanguy CC; Boumpoutou KR; Ntoumi F Int J Infect Dis; 2021 May; 106():3-7. PubMed ID: 33370565 [TBL] [Abstract][Full Text] [Related]
17. Seroprevalence of SARS-CoV-2 infection in the general population of Nepal during the first and second generalized waves of the COVID-19 pandemic-2020-2021. Paudel KP; Samuel R; Jha R; Pandey BD; Edirisuriya C; Shrestha NL; Gyawali P; Pokhrel A; Shrestha L; Mahato RK; Hossain SS; Arunkumar G; Bose AS; Dhimal M; Gautam D; Neupane S; Thakur N; Shrestha S; Bhusal N; Jha P; Gupta BP; Rayamajhi RB; Subedi KC; Kandel S; Poudel M; Thapa LB; Sharma GN; Gocotano AE; Sunny AK; Gautam R; Bhatta DR; Awale BK; Roka B; Ojha HC; Baral P; Adhikari MD; Lohani GR; Shrestha M; Singh DR; Aryal L; Pandav RS; Pokhrel R Influenza Other Respir Viruses; 2023 Dec; 17(12):e13234. PubMed ID: 38149926 [TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441 [TBL] [Abstract][Full Text] [Related]
19. Investigation of SARS-CoV-2 seroprevalence in relation to natural infection and vaccination between October 2020 and September 2021 in the Czech Republic: a prospective national cohort study. Thon V; Piler P; Pavlík T; Andrýsková L; Doležel K; Kostka D; Pikhart H; Bobák M; Klánová J BMJ Open; 2023 Mar; 13(3):e068258. PubMed ID: 36898746 [TBL] [Abstract][Full Text] [Related]
20. Extensive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission Associated With Low Mortality in Kinshasa, Democratic Republic of the Congo: For How Long? Colebunders RL; Kenyon C Clin Infect Dis; 2022 Mar; 74(5):891-892. PubMed ID: 34181705 [No Abstract] [Full Text] [Related] [Next] [New Search]